This article is more than 5 years old. Information may no longer be current.
Long-acting rilpivirine effective in three different doses
Click Here to Manage Email Alerts
SEATTLE — Researchers from London have found that 300 mg, 600 mg and 1,200 mg long-acting rilpivirine formulation resulted in prolonged plasma and genital tract exposure in a healthy cohort with low behavioral risk for HIV.
The prospective, open-label, stratified-dose study included 27 women aged between 18 and 50 years of African or African Caribbean descent from the St. Stephen’s Center in London. Women were screened for HIV and sexually transmitted infections as well as overall health.
A single intramuscular 300 mg, 600 mg and 1200 mg dose of long-acting rilpivirine were administered. Plasma samples to detect rilpivirine levels were obtained at baseline, and at 1, 3, 7, 11, 14, 21, 28, 42, 56 and 84 hours. Genital tract fluids were obtained at similar intervals beginning at 8 hours.
All doses were well tolerated with no serious adverse events reported.
The researchers also performed a sub-study including six male participants administered a 600mg dose of long-acting rilpivirine. Plasma pharmokinetics and rectal biopsies were obtained at days 7 and 14.
For more information:
- Jackson A. #35. Presented at:19th Conference on Retroviruses and Opportunistic Infections; March 3-8, 2012; Seattle.
Disclosures: The researchers report no relevant financial disclosures.
 |
Follow InfectiousDiseaseNews.com on Twitter. |